Guidance is lacking on the role of antipsychotics for managing patients with BPSD who have been taking risperidone for longer than 12 weeks. When risperidone is used for treatment of BPSD, patients should be reviewed regularly when starting to assess for efficacy and adverse effects and treatment ceased if they have not responded to an initial prescription. Risperidone is associated with a number of adverse effects, including an increased risk of cerebrovascular events and death. Risperidone is of modest benefit for some patients (up to 20%) in managing the symptoms of aggression and psychosis in short-term trials of 12 weeks when used for treatment of behavioural and psychological symptoms of dementia (BPSD). If risperidone treatment is required, the lowest dose possible should be used for a short period only. Non-pharmacological methods of treatment should be used first line for BPSD.Risperidone has minimal evidence of efficacy beyond 3 months and is associated with an increased risk of adverse events and mortality. Antipsychotics are only effective for one in five people with dementia for short-term management.
Risperdal recent news trial#
This item is for a treatment phase of continuing treatment, or a trial of reduction or cessation of treatment.
The previous Authority Required (STREAMLINED) listing was changed to an initial treatment phase.On 1 January 2020, changes were made to risperidone listings on the PBS General ScheduleĬhanges apply to risperidone for behavioural and psychological symptoms of dementia (BPSD) of the Alzheimer type to reduce inappropriate prescribing beyond 12 weeks.
0 kommentar(er)
